Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Translational Science"
DOI: 10.1111/cts.12728
Abstract: Ubrogepant is a novel, oral calcitonin gene‐related peptide (CGRP) receptor antagonist intended for the acute treatment of migraine attacks. Ubrogepant has a chemical structure distinct from previous small‐molecule CGRP receptor antagonists that were associated with… read more here.
Keywords: associated clinically; trial; hepatic safety; alanine aminotransferase ... See more keywords